Benzimidazole-2-one: A novel anchoring principle for antagonizing p53-Mdm2

被引:19
作者
Wang, Wei [1 ,2 ,3 ]
Cao, Haiping [1 ]
Wolf, Siglinde [4 ]
Camacho-Horvitz, Miguel S. [5 ]
Holak, Tad A. [4 ,6 ]
Domling, Alexander [1 ,7 ]
机构
[1] Univ Pittsburgh, Pittsburgh, PA 15213 USA
[2] Minist Educ, Key Lab Combinatorial Biosynth & Drug Discovery, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Sch Pharmaceut Sci, Wuhan 430071, Peoples R China
[4] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[5] Pittsburgh Allderdice High Sch, Pittsburgh, PA 15217 USA
[6] Jagiellonian Univ, Fac Chem, PL-30060 Krakow, Poland
[7] Univ Groningen, NL-9713 AV Groningen, Netherlands
基金
美国国家科学基金会;
关键词
Protein-protein interaction; ANCHOR; Tryptophan; Multicomponent reaction; Ugi; p53; mdm2; Selectivity; SUPPRESSOR TRANSACTIVATION DOMAIN; PROTEIN-PROTEIN INTERACTIONS; 3-COMPONENT REACTION; DRUG DISCOVERY; NMR; P53; INHIBITORS; MDM2; POTENT; DERIVATIVES;
D O I
10.1016/j.bmc.2012.06.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Herein we propose the benzimidazole-2-one substructure as a suitable tryptophan mimic and thus a reasonable starting point for the design of p53 Mdm2 antagonists. We devise a short multicomponent reaction route to hitherto unknown 2-(2-oxo-2,3-dihydro-1H-benzoidlimidazol-1-yl)acetamides by reacting mono N-carbamate protected phenylenediamine in a Ugi-3 CR followed by base induced cyclisation. Our preliminary synthesis and screening results are presented here. The finding of the benzimidazolone moiety as a tryptophan replacement in mdm2 is significant as it offers access to novel scaffolds with potentially higher selectivitY and potency and improved biological activities. Observing low mu M affinities to mdm2 by NMR and fluorescence polarization we conclude that the 2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetamide scaffold might be a good starting point to further optimize the affinities to Mdm2. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3982 / 3995
页数:14
相关论文
共 54 条
[1]   Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction [J].
Allen, John G. ;
Bourbeau, Matthew P. ;
Wohlhieter, G. Erich ;
Bartberger, Michael D. ;
Michelsen, Klaus ;
Hungate, Randall ;
Gadwood, Robert C. ;
Gaston, Rick D. ;
Evans, Bruce ;
Mann, Larry W. ;
Matison, Michael E. ;
Schneider, Stephen ;
Huang, Xin ;
Yu, Dongyin ;
Andrews, Paul S. ;
Reichelt, Andreas ;
Long, Alexander M. ;
Yakowec, Peter ;
Yang, Evelyn Y. ;
Lee, Tani Ann ;
Oliner, Jonathan D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7044-7053
[2]  
Andreeff M., 2010, AMERICAN SOCIETY OF
[3]  
[Anonymous], PEPT SCI
[4]   New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays [J].
Baell, Jonathan B. ;
Holloway, Georgina A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) :2719-2740
[5]   A Medicinal Chemist's Guide to Molecular Interactions [J].
Bissantz, Caterina ;
Kuhn, Bernd ;
Stahl, Martin .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5061-5084
[6]   Robust NMR Screening for Lead Compounds Using Tryptophan-Containing Proteins [J].
Bista, Michal ;
Kowalska, Kaja ;
Janczyk, Weronika ;
Doemling, Alexander ;
Holak, Tad A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (22) :7500-+
[7]  
Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P568, DOI 10.1038/nrclinonc.2011.134
[8]  
Czarna A., 2010, ANGEW CHEM, V122, P5480, DOI DOI 10.1002/ANGE.201001343
[9]   High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx [J].
Czarna, Anna ;
Popowicz, Grzegorz M. ;
Pecak, Aleksandra ;
Wolf, Siglinde ;
Dubin, Grzegorz ;
Holak, Tad A. .
CELL CYCLE, 2009, 8 (08) :1176-1184
[10]   Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy [J].
D'Silva, L ;
Ozdowy, P ;
Krajewski, M ;
Rothweiler, U ;
Singh, M ;
Holak, TA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (38) :13220-13226